Antioxidant supplementation for lung disease in cystic fibrosis.

BACKGROUND Airway infection leads to progressive damage of the lungs in cystic fibrosis and oxidative stress has been implicated in the etiology. Supplementation of antioxidant micronutrients (vitamin E, vitamin C, ß-carotene and selenium) or glutathione may therefore potentially help maintain an oxidant-antioxidant balance. Current literature suggests a relationship between oxidative status and lung function. OBJECTIVES To synthesize existing knowledge of the effect of antioxidants such as vitamin C, vitamin E, ß-carotene, selenium and glutathione in cystic fibrosis lung disease. SEARCH METHODS The Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register and PubMed were searched using detailed search strategies. We contacted authors of included studies and checked reference lists of these studies for additional, potentially relevant studies.Last search of Cystic Fibrosis Trials Register: 29 August 2013. SELECTION CRITERIA Randomized controlled studies and quasi-randomized controlled studies of people with cystic fibrosis comparing antioxidants as listed above (individually or in combination) in more than a single administration to placebo or standard care. DATA COLLECTION AND ANALYSIS Two authors independently selected studies, extracted data and assessed the risk of bias in the included studies. We contacted trial investigators to obtain missing information. Primary outcomes are lung function and quality of life; secondary outcomes are oxidative stress, inflammation, nutritional status, days on antibiotics and adverse events during supplementation. If meta-analysed, studies were subgrouped according to method of administration and the duration of supplementation. MAIN RESULTS One quasi-randomized and nine randomized controlled studies were included, with a total of 436 participants. Eight studies analyzed oral supplementation with antioxidants and two inhaled supplements.One study (n = 46) of an oral combined supplement demonstrated a significant difference in forced expiratory volume at one second expressed as per cent predicted after two weeks in favour of the control group, mean difference -4.30 (95% confidence interval -5.64 to -2.96); however a further study (n = 41) of oral supplementation with glutathione showed a significant improvement in this outcome and in forced vital capacity after six months from the treatment start, mean difference 17.40 (95% confidence interval 13.69 to 21.11) and 14.80 (95% confidence interval 9.66 to 19.94) respectively. The combined supplement study also indicated a significant improvement in quality of life favouring control, mean difference -0.06 points on the quality of well-being scale (95% confidence interval -0.12 to -0.01). Based on one study (n = 41) of oral glutathione supplementation in children, the supplements had a positive effect on the nutritional status (body mass index %) of the patients, mean difference 17.20 (95% confidence interval 12.17 to 22.23). In two studies (n = 83) that supplemented vitamin E, there was an improvement after two months in the blood levels of vitamin E, mean difference 11.78 μM/L (95% confidence interval 10.14 to 13.42).Based on one of the two studies of inhaled glutathione supplementation, there was an improvement in the forced expiratory volume at one second expressed as per cent predicted after three and six months (n = 153), mean difference 2.57 (95% confidence interval 2.24 to 2.90) and 0.97 (95% confidence interval 0.65 to 1.29) respectively. Only one of the studies reported quality of life data that could be analysed, but data showed no significant differences between treatment and control.None of the 10 included studies was judged to be free of bias. AUTHORS' CONCLUSIONS There appears to be conflicting evidence regarding the clinical effectiveness of antioxidant supplementation in cystic fibrosis. Based on the available evidence, glutathione (administered either orally or by inhalation) appears to improve lung function in some cases and decrease oxidative stress; however, due to the very intensive antibiotic treatment and other treatments that cystic fibrosis patients receive, the beneficial effect of antioxidants is very difficult to assess in patients with chronic infection without a very large population sample and a long-term (at least six months) study period. Further studies, especially in very young patients, examining clinically relevant outcomes, dose levels, timing and the elucidation of clear biological pathways by which oxidative stress is involved in cystic fibrosis, are necessary before a firm conclusion regarding effects of antioxidants supplementation can be drawn.

[1]  R. Lodha,et al.  Zinc Supplementation for One Year Among Children with Cystic Fibrosis Does Not Decrease Pulmonary Infection , 2016, Respiratory Care.

[2]  B. Schmitt,et al.  Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study. , 2015, Redox biology.

[3]  S. Hilton,et al.  Oral Reduced L-Glutathione Improves Growth in Pediatric Cystic Fibrosis Patients , 2015, Journal of pediatric gastroenterology and nutrition.

[4]  P. Abete,et al.  Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  C. Goss,et al.  Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[6]  M. Skov,et al.  The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection -- a pilot study. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  A. Chang,et al.  Vitamin D supplementation for cystic fibrosis. , 2014, The Cochrane database of systematic reviews.

[8]  P. Sly,et al.  Oxidation contributes to low glutathione in the airways of children with cystic fibrosis , 2014, European Respiratory Journal.

[9]  I. Megson,et al.  Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. , 2014, Pharmacology & therapeutics.

[10]  E. Nash,et al.  Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. , 2013, The Cochrane database of systematic reviews.

[11]  M. Ballmann,et al.  Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. , 2013, American journal of respiratory and critical care medicine.

[12]  S. Hilton,et al.  62 Oral reduced L-glutathione improves weight and calprotectin in pediatric cystic fibrosis patients , 2013 .

[13]  M. Ballmann,et al.  WS5.1 Inhaled glutathione in cystic fibrosis , 2012 .

[14]  V. Raia,et al.  51 Inhaled GSH tolerability in patients with cystic fibrosis (CF) , 2012 .

[15]  R. Gambari,et al.  Oxidative stress and antioxidant therapy in cystic fibrosis. , 2012, Biochimica et biophysica acta.

[16]  L. Shamseer,et al.  Antioxidant micronutrients for lung disease in cystic fibrosis. , 2010, The Cochrane database of systematic reviews.

[17]  M. Konstan,et al.  Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[18]  D. Turck,et al.  A new water-soluble oral vitamin E formulation in cystic fibrosis (CF) children , 2010 .

[19]  P. Sly,et al.  Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. , 2009, The Journal of pediatrics.

[20]  A. Munck,et al.  Bioavailability of oral vitamin E formulations in adult volunteers and children with chronic cholestasis or cystic fibrosis , 2009, Journal of clinical pharmacy and therapeutics.

[21]  J. Bargon,et al.  A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis , 2009, European journal of medical research.

[22]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[23]  C L Rock,et al.  Beta Carotene: From Biochemistry to Clinical Trials , 2009 .

[24]  Douglas G. Altman,et al.  Chapter 9: Analysing Data and Undertaking Meta-Analyses , 2008 .

[25]  D. Altman,et al.  Chapter 8: Assessing risk of bias in included studies , 2008 .

[26]  Cornelia M Ulrich,et al.  A mathematical model of glutathione metabolism , 2008, Theoretical Biology and Medical Modelling.

[27]  J. Abbott,et al.  Validation of the Italian version of the Cystic Fibrosis Quality of Life Questionnaire (CFQoL), a disease specific measure for adults and adolescents with cystic fibrosis. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[28]  F. Beck,et al.  Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis , 2008, Pediatric pulmonology.

[29]  B. Gaston,et al.  S-nitrosothiols signal hypoxia-mimetic vascular pathology. , 2007, The Journal of clinical investigation.

[30]  R. Kronmal,et al.  Association between pulmonary function and sputum biomarkers in cystic fibrosis. , 2007, American journal of respiratory and critical care medicine.

[31]  L. Herzenberg,et al.  High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  K. Grimwood,et al.  Vitamin A and E deficiency and lung disease in infants with cystic fibrosis , 2005, Journal of paediatrics and child health.

[33]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[34]  D. Lichtenberg,et al.  Lipid peroxidation cannot be used as a universal criterion of oxidative stress. , 2004, Progress in lipid research.

[35]  J. Ribalta,et al.  Effects of vitamin E and carotenoid status on oxidative stress in health and disease. Evidence obtained from human intervention studies. , 2003, Molecular aspects of medicine.

[36]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[37]  S. Mayne,et al.  Antioxidant nutrients and chronic disease: use of biomarkers of exposure and oxidative stress status in epidemiologic research. , 2003, The Journal of nutrition.

[38]  U. Wahn,et al.  The revised German Cystic Fibrosis Questionnaire: Validation of a disease-specific health-related quality of life instrument , 2003, Quality of Life Research.

[39]  U. Ozcelik,et al.  Antioxidant effect of β‐carotene in cystic fibrosis and bronchiectasis: clinical and laboratory parameters of a pilot study , 2002, Acta paediatrica.

[40]  L. Wood,et al.  Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients. , 2002, The American journal of clinical nutrition.

[41]  Douglas G Altman,et al.  Meta-analyses involving cross-over trials: methodological issues. , 2002, International journal of epidemiology.

[42]  Oermann Cm.  Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future. , 2001 .

[43]  L. Wood,et al.  Oxidative Stress in Cystic Fibrosis: Dietary and Metabolic Factors , 2001, Journal of the American College of Nutrition.

[44]  I. Elmadfa,et al.  Effects of β-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis , 2001, Thorax.

[45]  L. Bíró,et al.  Antioxidant Status in Patients with Cystic Fibrosis , 2000, Annals of Nutrition and Metabolism.

[46]  I. Elmadfa,et al.  Long-Term Oral β-Carotene Supplementation in Patients with Cystic Fibrosis – Effects on Antioxidative Status and Pulmonary Function , 2000, Annals of Nutrition and Metabolism.

[47]  B. Zemel,et al.  Longitudinal analysis shows serum carotenoid concentrations are low in children with cystic fibrosis. , 1999, Journal of the American Dietetic Association.

[48]  F. Kelly.  Gluthathione: in defence of the lung. , 1999, Food and Chemical Toxicology.

[49]  G. Bellon,et al.  Lipid Peroxidation and Antioxidant Defenses in Cystic Fibrosis Patients , 1999, Clinical chemistry and laboratory medicine.

[50]  P. Montuschi,et al.  8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. , 1998, American journal of respiratory and critical care medicine.

[51]  H. Schünemann,et al.  Oxidative stress and lung function. , 1997, American journal of epidemiology.

[52]  A Bast,et al.  Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. , 1997, American journal of respiratory and critical care medicine.

[53]  B. Winklhofer-Roob.  Vitamin E supplementation in cystic fibrosis. , 1997, Journal of pediatric gastroenterology and nutrition.

[54]  M. V. van’t Hof,et al.  Plasma vitamin C concentrations in patients with cystic fibrosis: evidence of associations with lung inflammation. , 1997, The American journal of clinical nutrition.

[55]  B. Winklhofer-Roob.  beta-Carotene, malondialdehyde, and cystic fibrosis. , 1997, The American journal of clinical nutrition.

[56]  C. Rock,et al.  Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids. , 1996, Journal of the American Dietetic Association.

[57]  S. Suter,et al.  Neutrophil Elastase/α1-Proteinase Inhibitor Complex Levels Decrease in Plasma of Cystic Fibrosis Patients during Long-Term Oral β-Carotene Supplementation1 , 1996, Pediatric Research.

[58]  B. Winklhofer-Roob.  Beta-carotene supplementation in cystic fibrosis. , 1996, The Journal of pediatrics.

[59]  R. Sokol,et al.  Supplementation with carotenoids corrects increased lipid peroxidation in children with cystic fibrosis. , 1996, The American journal of clinical nutrition.

[60]  F. Kelly,et al.  Vitamin E supplementation in cystic fibrosis. , 1996, Journal of pediatric gastroenterology and nutrition.

[61]  M. V. van’t Hof,et al.  Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. , 1996, The American journal of clinical nutrition.

[62]  D. Moher,et al.  Redundancy, disaggregation, and the integrity of medical research , 1996, The Lancet.

[63]  G. Mastella,et al.  Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation , 1996, European Journal of Pediatrics.

[64]  J. Price,et al.  Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. , 1996, The European respiratory journal.

[65]  M. V. van’t Hof,et al.  Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: improvement during vitamin E supplementation. , 1995, Free radical biology & medicine.

[66]  M. V. van’t Hof,et al.  Response to oral β‐carotene supplementation in patients with cystic fibrosis: a 16‐month follow‐up study , 1995 .

[67]  D. Homnick,et al.  Single- and multiple-dose-response relationships of beta-carotene in cystic fibrosis. , 1995, The Journal of pediatrics.

[68]  M. V. van’t Hof,et al.  Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during beta-carotene supplementation in cystic fibrosis. , 1995, Free radical biology & medicine.

[69]  O. Karg,et al.  [Combined respiratory dysregulation. Obstructive sleep apnea syndrome and chronic respiratory pump weakness in kyphoscoliosis]. , 1995, Medizinische Klinik.

[70]  H. Faure,et al.  Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis. , 1995, The American journal of clinical nutrition.

[71]  P. Farrell,et al.  Oral supplementation with a high-fat, high-energy product improves nutritional status and alters serum lipids in patients with cystic fibrosis. , 1995, Journal of the American Dietetic Association.

[72]  J. Arnaud,et al.  Effect of double-blind cross-over selenium supplementation on lipid peroxidation markers in cystic fibrosis patients. , 1995, Clinica chimica acta; international journal of clinical chemistry.

[73]  G. Jahreis,et al.  [The value of selenotherapy in patients with mucoviscidosis]. , 1995, Medizinische Klinik.

[74]  F. Kelly,et al.  Evidence for Increased oxidative Damage in Patients with Cystic Fibrosis , 1994, Pediatric Research.

[75]  B. Winklhofer-Roob.  Oxygen free radicals and antioxidants in cystic fibrosis: the concept of an oxidant‐antioxidant imbalance , 1994, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[76]  R. Crystal,et al.  Systemic deficiency of glutathione in cystic fibrosis. , 1993, Journal of applied physiology.

[77]  H. Faure,et al.  Effect of double-blind crossover selenium supplementation on biological indices of selenium status in cystic fibrosis patients. , 1993, Clinical chemistry.

[78]  S. Nasr,et al.  Correction of vitamin E deficiency with fat-soluble versus water-miscible preparations of vitamin E in patients with cystic fibrosis. , 1993, The Journal of pediatrics.

[79]  H. J. Mcclung,et al.  Vitamin E Deficiency Neuropathy in Children with Fat Malabsorption Studies in Cystic Fibrosis and Chronic Cholestasis a , 1989, Annals of the New York Academy of Sciences.

[80]  T. Hoogenraad.  Managing adults with cystic fibrosis. , 1989, BMJ.

[81]  C. Koch,et al.  N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility. , 1989, The European respiratory journal.

[82]  C. Koch,et al.  The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. , 1988, The European respiratory journal.

[83]  F. Ratjen,et al.  A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis , 1985, European Journal of Pediatrics.

[84]  David B. Pillemer,et al.  Summing Up: The Science of Reviewing Research , 1984 .

[85]  Zoirova Rr.  [Use of the mucolytic agent, mucosolvin, in multiple modality treatment of cystic fibrosis in children]. , 1983 .

[86]  E. Mitchell,et al.  Controlled trial of oral N‐acetylcysteine in cystic fibrosis , 1982, Australian paediatric journal.

[87]  M. Losowsky,et al.  Vitamin status in treated patients with cystic fibrosis. , 1981, Archives of disease in childhood.

[88]  J. Dodge,et al.  Dietary management of cystic fibrosis. , 1981, The Practitioner.

[89]  W. Warwick,et al.  Axonal Dystrophy in the Gracile Nucleus in Congenital Biliary Atresia and Cystic Fibrosis (Mucoviscidosis): Beneficial Effect of Vitamin E Therapy , 1980, Journal of neuropathology and experimental neurology.

[90]  V. Hubbard,et al.  Selenium and cystc fibrosis , 1980 .

[91]  P. di Sant'Agnese,et al.  The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis. , 1977, The Journal of clinical investigation.

[92]  S. Levin.  Letter: Muscular performance and vitamin E in cystic fibrosis. , 1974, Archives of disease in childhood.

[93]  M. Blackhall,et al.  INHIBITION OF PSEUDOMONAS ÆRUGINOSA BY ASCORBIC ACID ACTING SINGLY AND IN COMBINATION WITH ANTIMICROBIALS: IN‐VITRO AND IN‐VIVO STUDIES , 1974, The Medical journal of Australia.

[94]  M. Navab,et al.  POLYUNSATURATED FATTY ACIDS AND TOCOPHEROL LEVELS IN PATIENTS WITH CYSTIC FIBROSIS * , 1972, Annals of the New York Academy of Sciences.

[95]  D. Muller,et al.  Absorption of Different Doses of Fat Soluble and Water Miscible Preparations of Vitamin E in Children with Cystic Fibrosis , 1971, Archives of disease in childhood.

[96]  Howatt Wf,et al.  A double-blind study of the use of acetylcysteine in patients with cystic fibrosis. , 1966 .

[97]  P. di Sant'Agnese,et al.  Studies of tocopherol deficiency in infants and children. VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. , 1958, Pediatrics.

[98]  J. Kalbfleisch,et al.  Bioavailability of a Novel, Water-Soluble Vitamin E Formulation in Malabsorbing Patients , 2007, Digestive Diseases and Sciences.

[99]  R. Houwen,et al.  Dietary supplementation with multiple micronutrients: no beneficial effects in pediatric cystic fibrosis patients. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[100]  A. Coates,et al.  ‘ ‘ ATS / ERS TASK FORCE : STANDARDISATION OF LUNG FUNCTION TESTING , 2005 .

[101]  S. Hilton,et al.  A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. , 2005, Chest.

[102]  J. Hankinson,et al.  SERIES ''ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING'' Edited by V. Brusasco, R. Crapo and G. Viegi Number 5 in this Series Interpretative strategies for lung function tests , 2005 .

[103]  K. McCoy,et al.  Copper enzyme activities in cystic fibrosis before and after copper supplementation plus or minus zinc. , 2004, Metabolism: clinical and experimental.

[104]  L. Wood,et al.  Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. , 2003, The American journal of clinical nutrition.

[105]  I. Elmadfa,et al.  Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. , 1998, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[106]  C. Cross,et al.  Oxidative stress in cystic fibrosis: does it occur and does it matter? , 1997, Advances in pharmacology.

[107]  M. Schimek,et al.  Response of vitamin E deficient patients with cystic fibrosis (CF) to oral RRR-α-tocopherol or all-rac-α-tocopheryl acetate , 1992 .

[108]  P. Farrell,et al.  Nutritional assessment of infants with cystic fibrosis diagnosed through screening , 1991, Pediatric pulmonology. Supplement.

[109]  D. Bilton,et al.  Rationale for antioxidant therapy in pancreatitis and cystic fibrosis. , 1990, Advances in experimental medicine and biology.

[110]  J. Arnaud,et al.  Selenium and oxidant injury in patients with cystic fibrosis. , 1990, Advances in experimental medicine and biology.

[111]  M. Miller,et al.  The clinical effect of correction of vitamin E depletion in cystic fibrosis. , 1987, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[112]  M. Goodchild.  Practical management of nutrition and gastrointestinal tract in cystic fibrosis. , 1986, Journal of the Royal Society of Medicine.

[113]  C. Popow,et al.  Oral acetylcysteine in cystic fibrosis. A co-operative study. , 1980, European journal of respiratory diseases. Supplement.

[114]  A. Mitchell,et al.  The effect of supplemental vitamin E on vitamin A serum levels in cystic fibrosis. , 1978, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[115]  H. W. Rotthauwe,et al.  [Serum concentrations of vitamin A, carotene, retinol-binding protein and prealbumin in patients with cystic fibrosis (author's transl)]. , 1975, Zeitschrift fur Kinderheilkunde.

[116]  J. Zebrak,et al.  [Results in treatment of children with mucoviscidosis in a sanatorium]. , 1973, Zeitschrift fur Erkrankungen der Atmungsorgane mit Folia bronchologica.

[117]  C. Denning,et al.  Blood and Liver Concentrations of Vitamins A and E in Children with Cystic Fibrosis of the Pancreas , 1972, Pediatric Research.